Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), is pleased to announce that it has obtained a final order from the Ontario Superior Court of Justice approving the previously announced plan of arrangement (the “Arrangement”) with Sunovion Pharmaceuticals Inc. In addition, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to the Arrangement.

Receipt of the Final Order and the expiration of the HSR waiting period satisfy two of the conditions to the closing of the Arrangement, which remains subject to other customary closing conditions. Cynapsus expects that the Arrangement will be completed on or about October 21, 2016.

About Cynapsus
Cynapsus is a specialty central nervous system pharmaceutical company that has been developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. For additional company information, please visit www.cynapsus.ca.